IKTNCMHealthcare·Biotechnology#278 in industry

Inhibikase Therapeutics, Inc.

Reports in 16d· 2026-05-13

+11.8% · 90d

$1.89

+0.01 (+0.53%)

After-Hours $1.89(+0.00)

News

(1)

April 2026

Apr 7, 20262 weeks ago8-KHealthcare

Inhibikase Therapeutics, Inc. — 8-K Filing

IKTInhibikase Therapeutics, Inc.

# 🧾 What This Document Is This is a Form 8-K filing, which companies use to announce major news to investors. This specific announcement shares that Inhibikase Therapeutics has started its most important clinical trial yet—a **Phase 3 study** of their drug **IKT-001** for treating **Pulmonary Arte

Read summaryView on SEC EDGAR

Key Data

Market Cap$249.5M

Open$1.86

Prev Close$1.88

Day Range$1.85 – $1.92

52W Range$1.33 – $2.37

Volume688,928

P/E (TTM)—

EPS$-0.49

Dividend Yield—

Beta0.86

Price Target$6.00(+217.5%)

Next Earnings2026-05-13(16d)

Analyst Ratings

Strong Buy7 analysts

Buy 7Hold 0Sell 0

About

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Healthcare · Biotechnology

35 employees

www.inhibikase.com